Cost-effectiveness of pharmacist care for managing hypertension in Canada

Canadian Pharmacists Journal

Volumn 150, Issue 3, 2017, Pages 184-197

  Marra, Carlo ^a   Johnston, Karissa ^b   Santschi, Valerie ^c   Tsuyuki, Ross T ^d  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Broadstreet Health Economics and Outcomes Research   (Canada)

^c UNIVERSITY OF APPLIED SCIENCES WESTERN SWITZERLAND   (Switzerland)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE REGULATION; CANADA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; ECONOMIC ASPECT; END STAGE RENAL DISEASE; FRAMINGHAM RISK SCORE; HAZARD RATIO; HEALTH IMPACT ASSESSMENT; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PATIENT CARE; PHARMACIST; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC BLOOD PRESSURE; TRAINING;

EID: 85018950108     PISSN: 17151635     EISSN: 1913701X     Source Type: Journal    
DOI: 10.1177/1715163517701109     Document Type: Article

References (35)

1. Ezzati M, Lopez AD, Rodgers A. Selected major risk factors and global and regional burden of disease. Lancet 2002;360(9343):1347-60.
2. Zhou B, Bentham J, Di Cesare M. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 2017;389(10064):37-55.
3. World Health Organization. WHO global atlas of cardiovascular disease. Available: www.who.int/cardiovascular_diseases/en/ (accessed Mar. 2, 2017).
4. Bakris G, Sarafidis P, Agarwal R, Ruilope L. Review of blood pressure control rates and outcomes. J Am Soc Hypertens 2014;8(2):127-41.
5. Padwal RS, Bienek A, McAlister FA, Campbell NR. Epidemiology of hypertension in Canada: an update. Can J Cardiol 2016;32(5):687-94.
6. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275(20):1571-6.
7. Leung AA, Nerenberg K, Daskalopoulou SS. Hypertension Canada’s 2016 Canadian Hypertension Education Program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention and treatment of hypertension. Can J Cardiol 2016;32(5):569-88.
8. Yusuf S, Hawken S, Ounpuu S. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937-52.
9. Santschi V, Chiolero A, Colosimo AL. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc 2014;3(2):e000718.
10. Tsuyuki RT, Houle SK, Charrois TL. Randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: the Alberta Clinical Trial in Optimizing Hypertension (RxACTION). Circulation 2015;132(2):93-100.
11. D’Agostino RB, Sr. Vasan RS, Pencina MJ. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117(6):743-53.
12. Pencina MJ, D’Agostino RB, Sr. Larson MG. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation 2009;119(24):3078-84.
13. Framingham Heart Study. A project of the National Heart, Lung and Blood Institute and Boston University. Available: www.framinghamheartstudy.org (accessed Mar. 2, 2017).
14. Blood Pressure Lowering Treatment Trialists’ Collaboration, Ying A, Arima H. Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials. Lancet 2015;385(9971):867-74.
15. Hsu CY, McCulloch CE, Darbinian J. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005;165(8):923-8.
16. Chobanian AV, Bakris GL, Black HR. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206-52.
17. Pocock SJ, McCormack V, Gueyffier F. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ 2001;323(7304):75-81.
18. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005;43(7):736-49.
19. Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 2014;384(9943):591-8.
20. Mittmann N, Seung SJ, Hill MD. Impact of disability status on ischemic stroke costs in Canada in the first year. Can J Neurol Sci 2012;39(6):793-800.
21. Sorensen SV, Kansal AR, Connolly S. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011;105(5):908-19.
22. Bentkover JD, Stewart EJ, Ignaszewski A. New technologies and potential cost savings related to morbidity and mortality reduction in class III/IV heart failure patients in Canada. Int J Cardiol 2003;88(1):33-41.
23. McGillion MH, Croxford R, Watt-Watson J. Cost of illness for chronic stable angina patients enrolled in a self-management education trial. Can J Cardiol 2008;24(10):759-64.
24. Coyle D, Coyle K, Cameron C. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health 2013;16(4):498-506.
25. Manns BJ, Mendelssohn DC, Taub KJ. The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care. Int J Health Care Finance Econ 2007;7(2-3):149-69.
26. Canadian Institute of Health Information. National health expenditure trends. Table E. 1.16.2. Available: https://secure.cihi.ca/free_products/nhex_trends_narrative_report_2015_en.pdf (accessed Mar. 2, 2017).
27. Canadian Pharmacists Association. 2016 fees and claims data for government-sponsored pharmacist services, by province. 2016. Available: www.cfpnet.ca/bank/document_en/84-2015-provincial-chart.pdf (accessed Mar. 2, 2017).
28. Tsuyuki RT, Al Hamarneh YN, Jones CA, Hemmelgarn BR. The effectiveness of pharmacist interventions on cardiovascular risk: the multicenter randomized controlled RxEACH Trial. J Am Coll Cardiol 2016;67(24):2846-54.
29. Statistics Canada. Table 326-0021 Consumer Price Index. 2002. Available: http://www5.statcan.gc.ca/cansim/a26?id=3260021 (accessed Mar. 2, 2017).
30. Moran AE, Odden MC, Thanataveerat A. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med 2015;372(5):447-55.
31. James PA, Oparil S, Carter BL. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311(5):507-20.
32. Carter BL, Coffey CS, Ardery G. A cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pressure control. Circ Cardiovasc Qual Outcomes 2015;8(3):235-43.
33. Polgreen LA, Han J, Carter BL. Cost effectiveness of a physician-pharmacist collaboration intervention to improve blood pressure control. Hypertension 2015;66(6):1145-51.
34. Drummond M, Sculpher M, Torrance G. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford (UK): Oxford University Press; 2005.
35. Leenen FH, Dumais J, McInnis NH. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008;178(11):1441-9.